Significant  ||| S:0 E:12 ||| JJ
reduction  ||| S:12 E:22 ||| NN
of  ||| S:22 E:25 ||| IN
central  ||| S:25 E:33 ||| JJ
line-associated  ||| S:33 E:49 ||| JJ
bloodstream  ||| S:49 E:61 ||| JJ
infection  ||| S:61 E:71 ||| NN
rates  ||| S:71 E:77 ||| NNS
in  ||| S:77 E:80 ||| IN
a  ||| S:80 E:82 ||| DT
tertiary  ||| S:82 E:91 ||| JJ
neonatal  ||| S:91 E:100 ||| JJ
unit  ||| S:100 E:105 ||| NN
To  ||| S:105 E:108 ||| TO
evaluate  ||| S:108 E:117 ||| VB
the  ||| S:117 E:121 ||| DT
effectiveness  ||| S:121 E:135 ||| NN
of  ||| S:135 E:138 ||| IN
a  ||| S:138 E:140 ||| DT
quality  ||| S:140 E:148 ||| NN
initiative  ||| S:148 E:159 ||| NN
in  ||| S:159 E:162 ||| IN
reducing  ||| S:162 E:171 ||| VBG
central  ||| S:171 E:179 ||| JJ
line-associated  ||| S:179 E:195 ||| JJ
bloodstream  ||| S:195 E:207 ||| NN
infections  ||| S:207 E:218 ||| NNS
( ||| S:218 E:219 ||| -LRB-
CLABSIs ||| S:219 E:226 ||| NNP
)  ||| S:226 E:228 ||| -RRB-
in  ||| S:228 E:231 ||| IN
our  ||| S:231 E:235 ||| PRP$
neonatal  ||| S:235 E:244 ||| JJ
intensive  ||| S:244 E:254 ||| JJ
care  ||| S:254 E:259 ||| NN
unit ||| S:259 E:263 ||| NN
,  ||| S:263 E:265 ||| ,
we  ||| S:265 E:268 ||| PRP
designed  ||| S:268 E:277 ||| VBD
a  ||| S:277 E:279 ||| DT
prospective  ||| S:279 E:291 ||| JJ
study  ||| S:291 E:297 ||| NN
( ||| S:297 E:298 ||| -LRB-
January  ||| S:298 E:306 ||| NNP
2012-September  ||| S:306 E:321 ||| CD
2013 ||| S:321 E:325 ||| CD
)  ||| S:325 E:327 ||| -RRB-
estimating  ||| S:327 E:338 ||| VBG
CLABSI  ||| S:338 E:345 ||| NNP
incidence  ||| S:345 E:355 ||| NN
before  ||| S:355 E:362 ||| IN
and  ||| S:362 E:366 ||| CC
after  ||| S:366 E:372 ||| IN
our  ||| S:372 E:376 ||| PRP$
implementation ||| S:376 E:390 ||| NN
.  ||| S:390 E:392 ||| .
CLABSI  ||| S:392 E:399 ||| NNP
rates  ||| S:399 E:405 ||| NNS
were  ||| S:405 E:410 ||| VBD
significantly  ||| S:410 E:424 ||| RB
decreased  ||| S:424 E:434 ||| VBN
after  ||| S:434 E:440 ||| IN
our  ||| S:440 E:444 ||| PRP$
intervention ||| S:444 E:456 ||| NN
,  ||| S:456 E:458 ||| ,
from  ||| S:458 E:463 ||| IN
12  ||| S:463 E:466 ||| CD
cases  ||| S:466 E:472 ||| NNS
per  ||| S:472 E:476 ||| IN
1,000  ||| S:476 E:482 ||| CD
central  ||| S:482 E:490 ||| JJ
vascular  ||| S:490 E:499 ||| JJ
catheter  ||| S:499 E:508 ||| NN
( ||| S:508 E:509 ||| -LRB-
CVC ||| S:509 E:512 ||| NNP
)  ||| S:512 E:514 ||| -RRB-
days  ||| S:514 E:519 ||| NNS
during  ||| S:519 E:526 ||| IN
the  ||| S:526 E:530 ||| DT
preinterventional  ||| S:530 E:548 ||| JJ
period  ||| S:548 E:555 ||| NN
to  ||| S:555 E:558 ||| TO
3.4  ||| S:558 E:562 ||| CD
cases  ||| S:562 E:568 ||| NNS
per  ||| S:568 E:572 ||| IN
1,000  ||| S:572 E:578 ||| CD
CVC  ||| S:578 E:582 ||| NN
days  ||| S:582 E:587 ||| NNS
during  ||| S:587 E:594 ||| IN
the  ||| S:594 E:598 ||| DT
postinterventional  ||| S:598 E:617 ||| JJ
period  ||| S:617 E:624 ||| NN
( ||| S:624 E:625 ||| -LRB-
P  ||| S:625 E:627 ||| CD
=  ||| S:627 E:629 ||| CD
.004 ||| S:629 E:633 ||| CD
) ||| S:633 E:634 ||| -RRB-
.  ||| S:634 E:636 ||| .
